Stollery Children's Hospital, University of Alberta, Edmonton, Alberta.
Pediatrics, Division of Cardiology, University of Colorado, Denver Anschutz Medical Campus, Children's Hospital Colorado Aurora, Colorado.
J Heart Lung Transplant. 2022 Mar;41(3):327-333. doi: 10.1016/j.healun.2021.11.003. Epub 2021 Nov 19.
Reports focused on adult heart transplant (HTx) recipients with COVID-19 suggest an increased risk of severe disease, however; it is unclear if this holds true for pediatric HTx patients, given the typically milder course of illness in children in general with COVID-19. We sought to rapidly implement a system for multi-center data collection on pediatric HTx candidates and recipients, with the aim of describing the patient population and infection related outcomes.
The Pediatric Heart Transplant Society (PHTS) is a multi-center collaboration that seeks to improve the outcomes of children who are listed and undergo HTx. The society consists of pediatric HTx centers in North America (n = 53), UK (n = 2), and Brazil (n = 1). In response to the pandemic, PHTS developed a web-based platform to collect COVID-19 specific data on pediatric HTx candidates and recipients. Non-PHTS centers were also invited to submit data. Data fields included pre-and post-HTx patient characteristics, presumed versus documented infection, need for hospitalization (including ICU and ventilator use), treatments administered, and 30-day outcome (resolution, death, sequelae, and or unresolved) RESULTS: Data collection was initiated on 4/30/20. As of 03/15/21 there were 225 patients [19 pre-HTx and 206 post-HTx, median age 14 years (IQR 7, 18)] reported from 41 centers. Hospitalization occurred in 42% (n = 8) of the pre-HTx and 21% (n=43) of the post-HTx patients. Among the patients listed for HTx, 21% (n = 4) required ICU and 10.5% (n = 2) were mechanically ventilated. Among post-HTx patients, 7% (n = 14) required ICU and 1% (n = 3) were mechanically ventilated. At 30 days, the majority of patients had resolution of symptoms (94.7% pre-HTx, 95.6% post-HTx). One death was reported in a post-HTx patient prior to 30 days from onset of COVID-19 illness.
These data demonstrate the ability to rapidly adapt the PHTS data collection infrastructure in response to a novel infection and represent the first known multi-center report of characteristics and early outcomes for patients listed and following pediatric HTx with COVID-19. Hospitalization appears to be more common for both candidates and recipients due to COVID-19 than for the general pediatric population though stays were short and mortality minimal.
针对 COVID-19 成年心脏移植(HTx)受者的报告表明,严重疾病的风险增加,然而;鉴于儿童 COVID-19 的一般疾病过程通常较轻,尚不清楚这是否适用于儿科 HTx 患者。我们旨在迅速建立一个多中心儿科 HTx 候选人和受者数据收集系统,目的是描述患者人群和感染相关结局。
儿科心脏移植协会(PHTS)是一个多中心合作组织,旨在改善接受 HTx 患儿的预后。该协会由北美(n=53)、英国(n=2)和巴西(n=1)的儿科 HTx 中心组成。为应对大流行,PHTS 开发了一个基于网络的平台,用于收集儿科 HTx 候选人和受者的 COVID-19 特定数据。还邀请非 PHTS 中心提交数据。数据字段包括 HTx 前和 HTx 后患者特征、假定感染与确诊感染、住院需求(包括 ICU 和呼吸机使用)、治疗方法和 30 天结局(缓解、死亡、后遗症和/或未解决)。
数据收集于 4 月 30 日开始。截至 2021 年 3 月 15 日,来自 41 个中心的 225 名患者(19 名 HTx 前患者和 206 名 HTx 后患者,中位年龄 14 岁(IQR7,18))报告了数据。21%(n=43)的 HTx 后患者住院。在等待 HTx 的患者中,21%(n=4)需要 ICU 治疗,10.5%(n=2)需要机械通气。在 HTx 后患者中,7%(n=14)需要 ICU 治疗,1%(n=3)需要机械通气。30 天时,大多数患者症状缓解(HTx 前 94.7%,HTx 后 95.6%)。1 例 HTx 后患者在 COVID-19 发病后 30 天内死亡。
这些数据表明,能够迅速适应 PHTS 数据收集基础设施以应对新的感染,代表了首例已知的多中心报告,报告了 COVID-19 患儿列出和接受儿科 HTx 的特征和早期结局。由于 COVID-19,候选人和受者的住院率似乎高于一般儿科人群,但住院时间短,死亡率低。